Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2005
10/13/2005WO2005094391A2 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
10/13/2005WO2005094364A2 Iga antibody protein as a cytotoxic drug
10/13/2005WO2005094348A2 Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
10/13/2005WO2005082415A3 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
10/13/2005WO2005079841A3 Gm1 binding deficient exotoxins for use as immunoadjuvants
10/13/2005WO2005079766A3 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
10/13/2005WO2005069717A3 The use os anti-rh antibodies for treating acute thrombocytopenia associated with dengue hemorrhagic fever, hepatitis c and other microbial infections
10/13/2005WO2005062972A3 Treatment of cancer with novel anti-il 13 monoclonal antibodies
10/13/2005WO2005058352A3 Treatment of rheumatoid arthritis with galectin-3 antagonists
10/13/2005WO2005056769A3 Orally-administered live bacterial vaccines for plague
10/13/2005WO2005051291A3 B-cell-targeted toxin for immuno response reduction
10/13/2005WO2005037313A3 Tissue repair by modulation of beta-1 integrin biological function
10/13/2005WO2005035558A3 Piscirickettsia salmonis antigens and use thereof
10/13/2005WO2005021032A9 Live attenuated aldolase-negative bacterial vaccine
10/13/2005WO2005014654A3 Product comprising a c4bp core protein and a monomeric antigen, and its use
10/13/2005WO2005009378A3 Polypeptides for inducing a protective immune response against staphylococcus aureus
10/13/2005WO2004085466A8 Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
10/13/2005WO2004062578A3 Methods for reducing mortality associated with acute myocardial infarction
10/13/2005WO2003068954A8 Microorganism for genetic therapeutic treatment of proliferative diseases
10/13/2005US20050229264 Recombinant gelatins
10/13/2005US20050228003 Mitotic kinesin inhibitors
10/13/2005US20050227988 compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety
10/13/2005US20050227951 Verification of translation
10/13/2005US20050227942 Use of Asialo-Gm1 (Agm1,) and/or GM gangliosides, and substances which simulate carbohydrate moiety of these gangliosides with regard to binding to anti-AGM1 antibodies and/or anti-GM1 antibodies, for the preparation of an agent for binding or blocking anti-AGM1 antibodies and/or anti-GM1 antibodies
10/13/2005US20050227924 Peyer's patch and/or M-cell targeting ligands
10/13/2005US20050227351 Methods and compound protein molecules used for inducing cytotoxic cell-mediated immune response in a mammal against a pathogenic cell
10/13/2005US20050227328 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/13/2005US20050227292 Allergenic protein complex of natural rubber latex
10/13/2005US20050227289 Antibodies to erythropoietin receptor and uses thereof
10/13/2005US20050227287 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPSc
10/13/2005US20050227277 Apoptosis proteins
10/13/2005US20050227253 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
10/13/2005US20050227233 Method for diagnosing and treating schizophrenia
10/13/2005US20050227224 Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
10/13/2005US20050226937 Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants
10/13/2005US20050226897 Method of protecting against coccidiosis
10/13/2005US20050226896 Administering to the host a live Plasmodium organism that is genetically engineered to disrupt a gene whose expression is up-regulated in liver stage parasites and whose function is not required for entry into host hepatocytes
10/13/2005US20050226895 vaccine to protect salmon against infection by Piscirickettsia salmonis, a gramnegative bacteria; salmonid rickettsial septicaemia
10/13/2005US20050226894 Oral vaccination
10/13/2005US20050226893 Lyophilization method to improve excipient crystallization
10/13/2005US20050226892 Methods and compositions comprising bacteriophage nanoparticles
10/13/2005US20050226891 Multiple antigenic peptides immunogenic against Streptococcus pneumonia
10/13/2005US20050226890 Tat-based vaccine compositions and methods of making and using same
10/13/2005US20050226889 Inhibition of viral infection and spread with viral and RhoA-derived peptides
10/13/2005US20050226888 Methods for generating immunity to antigen
10/13/2005US20050226887 Mucin antigen vaccine
10/13/2005US20050226886 Preferential detection of procarboxypeptidase R (thrombin activatable fibrinolyisis inhibitor) by enzyme-linked immunosorbent assay
10/13/2005US20050226885 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
10/13/2005US20050226884 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy
10/13/2005US20050226883 Humanized antibody
10/13/2005US20050226882 Method and multicomponent conjugates for treating cancer
10/13/2005US20050226881 Isolated peptide which binds to HLA-Cw*07 and uses thereof
10/13/2005US20050226880 Use of a preparation based on an antibody directed against a tumor-associated glycosylation
10/13/2005US20050226879 Methods and compositions related to inhibiting nuclear envelope breakdown
10/13/2005US20050226878 Immune Response Modifiers; toll-like receptor 7, 8, or 9 agonists; imidazonaphthyridine, oxazolo- or thiazolo-naphthyridine, quinoline, or pyridine amines, and an antiinflammatory glucocorticoid, immunosuppressant, or immunotherapeutic, or a non-steroidal antiinflammatory agent; side effect reduction
10/13/2005US20050226877 administration of a function blocking antibody which is capable of binding an epitope of VLA-1; arthritis
10/13/2005US20050226876 Anti-P-selectin antibodies
10/13/2005US20050226875 Uses of anti-CTLA-4 antibodies
10/13/2005US20050226873 Medical devices and methods for modulating cell adhesion
10/13/2005US20050226872 Use of cd25 binding molecules in the treatmnet of inflammatory diseases of the gastrointestinal tract
10/13/2005US20050226871 Using mixture of fk-506 and geldanamycin compound immobilized onto polypeptide; both compounds bind to polypeptide components of steroid receptor complexes, hsp90 and FKBP52, respectively
10/13/2005US20050226870 Administering anti-inflammatory amount of a purified antibody specific against C5, wherein antibody inhibits the cleavage of C5 into C5a and C5b
10/13/2005US20050226869 inhibiting the growth of a cell that expresses a protein of the invention; antitumor agents; identify polypeptides, cell membrane-associated, secreted or intracellular polypeptides whose expression is specifically limited to only a single (or very limited number of different) tissue type(s)
10/13/2005US20050226868 Method for treating tumors using anti-osteopontin antibodies
10/13/2005US20050226867 Immunoglobulin specific to interleukin receptor-5 (IL-R) for preventing and treating allergic disorders; immunotherapy
10/13/2005US20050226866 Bone morphogenic protein specific immunoglobulin for treatment of bone diseases; immunotherapy
10/13/2005US20050226865 Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin
10/13/2005US20050226864 Alteration of Fc-fusion protein serum half-lives by mutagenesis
10/13/2005US20050226863 Single-domain antibodies and uses thereof
10/13/2005US20050226861 Immunogen adherence inhibitor and method of making and using same
10/13/2005US20050226854 treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof by transplanting into the subject tissue derived from a human or porcine kidney or liver, the kidney or liver being at a selected gestational stage
10/13/2005US20050226849 Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses
10/13/2005US20050226846 Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression
10/13/2005US20050226812 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
10/13/2005US20050223628 Fuel additive
10/13/2005DE102004015179A1 Antigen des PM-2 Antikörpers und dessen Verwendung Antigen of the PM-2 antibody and the use thereof
10/13/2005DE102004013335A1 Impfstoff gegen Influenza basierend auf Geflügelpestviren Influenza vaccine based on avian influenza
10/13/2005DE10120630B4 Verwendung von Bulbophyllum neilgherrense zur Behandlung von Störungen des Herz-Kreislaufsystems Use of Bulbophyllum neilgherrense for the treatment of disorders of the cardiovascular system
10/13/2005CA2563117A1 Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor
10/13/2005CA2563024A1 Method for treating autoimmune diseases with antibodies
10/13/2005CA2562953A1 Humanized and chimeric anti-osm antibodies
10/13/2005CA2562038A1 Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
10/13/2005CA2561835A1 Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
10/13/2005CA2561732A1 Antibody drug
10/13/2005CA2561405A1 Monoclonal antibodies to gastrin hormone
10/13/2005CA2561376A1 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
10/13/2005CA2561111A1 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
10/13/2005CA2560889A1 Monoclonal antibodies specific for human ox40l (cd 134l)
10/13/2005CA2558435A1 Methods for inducing autolysis in infectious bacteria
10/13/2005CA2556227A1 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
10/13/2005CA2545512A1 Methods of identifying neoplasm-specific antibodies and uses thereof
10/13/2005CA2539043A1 Compositions capable of facilitating penetration across a biological barrier
10/12/2005EP1584685A2 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
10/12/2005EP1584628A2 Viral protein
10/12/2005EP1584627A1 Dimerized peptide
10/12/2005EP1583823A2 Isolation and identification of cross-reactive t cells
10/12/2005EP1583773A1 Polypeptides f' of the hepatitis c virus, epitopes, and the diagnostic and therapeutic applications thereof
10/12/2005EP1583558A2 Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection
10/12/2005EP1583557A2 Vaccine compositions and methods
10/12/2005EP1583506A2 Eye-drop vaccine containing copolymer 1 for therapeutic immunization
1 ... 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 ... 1823